Back to top

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 ...

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (E

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Rezolute, Inc. (RZLT)